Moneta Group Investment Advisors LLC Increases Position in Amgen, Inc. (NASDAQ:AMGN)
Moneta Group Investment Advisors LLC increased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 2,164.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,023 shares of the medical research company’s stock after purchasing an additional 63,107 shares during the period. Moneta Group Investment Advisors LLC’s holdings in Amgen were worth $529,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Gifford Fong Associates grew its position in shares of Amgen by 25.3% during the second quarter. Gifford Fong Associates now owns 67,671 shares of the medical research company’s stock valued at $12,470,000 after purchasing an additional 13,671 shares in the last quarter. Bray Capital Advisors increased its stake in Amgen by 11.6% in the 2nd quarter. Bray Capital Advisors now owns 19,676 shares of the medical research company’s stock worth $3,626,000 after acquiring an additional 2,045 shares during the last quarter. Weaver Consulting Group bought a new stake in Amgen in the 1st quarter worth approximately $239,000. CHICAGO TRUST Co NA increased its stake in Amgen by 2.8% in the 2nd quarter. CHICAGO TRUST Co NA now owns 3,716 shares of the medical research company’s stock worth $685,000 after acquiring an additional 100 shares during the last quarter. Finally, BHK Investment Advisors LLC raised its holdings in shares of Amgen by 3.9% during the 2nd quarter. BHK Investment Advisors LLC now owns 2,197 shares of the medical research company’s stock worth $405,000 after acquiring an additional 82 shares in the last quarter. Institutional investors own 76.28% of the company’s stock.
Shares of AMGN stock traded down $1.44 during trading hours on Wednesday, reaching $195.43. 1,028,251 shares of the stock were exchanged, compared to its average volume of 2,929,147. The firm has a market capitalization of $121.34 billion, a price-to-earnings ratio of 13.57, a price-to-earnings-growth ratio of 2.37 and a beta of 1.11. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $211.90. The company’s 50-day moving average price is $195.79 and its 200-day moving average price is $185.11. The company has a current ratio of 2.89, a quick ratio of 2.60 and a debt-to-equity ratio of 2.58.
The firm also recently declared a quarterly dividend, which was paid on Friday, September 6th. Stockholders of record on Thursday, August 15th were issued a $1.45 dividend. The ex-dividend date was Wednesday, August 14th. This represents a $5.80 annualized dividend and a dividend yield of 2.97%. Amgen’s payout ratio is 40.28%.
AMGN has been the subject of a number of recent research reports. Morgan Stanley cut their target price on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a report on Monday, July 15th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $230.00 price target (up previously from $221.00) on shares of Amgen in a research note on Thursday, September 5th. William Blair reaffirmed a “hold” rating on shares of Amgen in a research note on Friday, August 30th. Royal Bank of Canada increased their price objective on shares of Amgen from $192.00 to $206.00 and gave the company a “sector perform” rating in a research report on Tuesday, August 27th. Finally, Oppenheimer lifted their price objective on shares of Amgen from $230.00 to $240.00 in a research note on Tuesday, August 27th. Eleven research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Amgen presently has an average rating of “Hold” and a consensus target price of $217.33.
In other news, SVP Cynthia M. Patton sold 13,426 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $208.07, for a total value of $2,793,547.82. Following the transaction, the senior vice president now directly owns 32,648 shares in the company, valued at $6,793,069.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the completion of the transaction, the director now owns 16,336 shares in the company, valued at $3,064,306.88. The disclosure for this sale can be found here. Insiders have sold a total of 17,851 shares of company stock valued at $3,659,900 over the last three months. 0.25% of the stock is owned by corporate insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: What is Compound Interest?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.